Skip to main content
. Author manuscript; available in PMC: 2012 Apr 20.
Published in final edited form as: Nature. 2011 Oct 19;478(7369):404–407. doi: 10.1038/nature10486

Figure 1. Silencing of miR-33a/b in non-human primates.

Figure 1

(a) Experimental outline of anti-miR33 or mismatch control oligonucleotide treatment in African green monkeys (n=6/group). (b) Serum transaminase (AST, ALT), bilirubin and creatinine levels. (c) Hepatic gene expression in anti-miR treated monkeys fed a chow diet (4 weeks), or a high carbohydrate, moderate cholesterol diet (12 weeks). (d) Quantitation of miR-33a and b levels in anti-miR treated monkeys. (e) Western blot for hepatic ABCA1, CPT1 and CROT following 12 weeks of anti-miR treatment. (f) Expression of hepatic SREBP1 mRNA and its downstream genes, and (g) SREBP1 protein after 12 weeks of anti-miR treatment. (h) Hepatic PRKAA1 and SIRT6 mRNA after 12 weeks of anti-miR treatment. Data are the mean ± SEM. *P ≤ 0.05.